German biotechnology company
QIAGEN N.V. is a German-founded multinational provider of sample and assay technologies for molecular diagnostics, applied testing, academic research, and pharmaceutical research. The company operates in more than 35 offices in over 25 countries. QIAGEN N.V., the global corporate headquarter of the QIAGEN group, is located in Venlo, The Netherlands. The main operative headquarters are located in Hilden, Germany.[3] European, American, Chinese, and Asian-Pacific regional headquarters are located respectively in respectively Hilden, Germany; Germantown, Maryland, United States; Shanghai, China; and Singapore.[4] QIAGEN's shares are listed at the NYSE (using ticker QGEN) and at the Frankfurt Stock Exchange in the Prime Standard (using ticker QIA). Thierry Bernard is the company's Chief Executive Officer (CEO).
History
In 1984, QIAGEN was established on November 29 by a team of scientists at the Heinrich Heine University Düsseldorf, Germany. Two years later, QIAGEN launched its first product. A kit for the purification of plasmids—small ring-shaped DNA molecules in bacterial cells.[5] 1996 saw the initial public offering of QIAGEN on the technology-oriented Nasdaq stock exchange, becoming the first German company to do so.[6] 1997 saw the initial public offering on the Frankfurt Stock Exchange in Germany.[7]
Acquisitions
Qiagen Acquisitions
- Qiagen
- Molecular Staging, Inc. (Acq 2004)
- Digene (Acq 2007)
- Corbett Life Science (Acq 2008)
- DxS Ltd (Acq 2009)
- SABiosciences Corp. (Acq 2009)
- ESE GmbH (Acq 2010)
- Ipsogen S.A. (Acq 2011)
- Cellestis Limited (Acq 2011)
- Ingenuity Systems (Acq 2013)
- CLC bio (Acq 2013)
- Exiqon (Acq 2016)
- STAT-Dx (Acq 2018)
- Formulatrix (Acq 2019)
- OmicSoft (Acq 2017)
- N-of-One (Acq 2019)
- Molecular Staging, Inc. (Acq 2020)
- NeuMoDx Molecular Inc (Acq 2020)
- Verogen (Acq 2023)
2020 Thermo Fisher Acquisition Target
On March 3, 2020, Thermo Fisher Scientific announced plans for the acquisition of QIAGEN at €39 per share in cash, which valued the transaction at $11.5 billion at the time.[8]
The day after an open letter by hedge fund Davidson Kempner Capital Management, one of QIAGEN's largest shareholders, to reject the bid as undervalued,[9] Thermo Fisher raised their tender by 10% to €43 per share, an advance of $1B in value.[10] Davidson Kempner subsequently increased their holdings from 5.1% to 7.3% of QIAGEN.[11]
The acquisition offer was terminated on August 13, 2020, having only reached the threshold of 47% shareholder approval, below the minimum 66.6% required as per the agreement. Davidson Kempner was notable for having continued to reject the bid. Because of the lapsed offer, QIAGEN was required to reimburse $95 Million to Thermo Fisher in expenses.[12]
On August 21, the chairman of the company's supervisory board, Håkan Björklund, stepped down to be immediately replaced by Lawrence Rosen.[13]
Resulting from the failed takeover bid, QIAGEN announced it would buy the outstanding 80.1% of shares in NeuMoDx Molecular Inc., which it did not already own, for about $234 million.[14]
US$1.97 billion (2023)
US$3.81 billion (2023)
